TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03256695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol sulfate (ABS)
Description: ABS will be administered via eMDPI as per the dose and schedule specified in the arm.
Study: NCT05853445

Intervention type: OTHER
Intervention: Jakavi
Description: Prospective observational study. There is no treatment allocation. Patients administered Jakavi by prescription and administered according to the SmPC.
Study: NCT00817284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab and Irinotecan and radiotherapy
Description: * Bevacizumab 10 mg/kg is administered on days 1 and 15.~* Irinotecan:~* Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).~* Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.~* During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Temozolomide and radiotherapy
Description: Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.~Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.~After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.~Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy.
Study: NCT01327430

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk phospholipid
Description: During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
Study: NCT01411371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation of persistent atrial fibrillation
Description: Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment alone
Description: Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
Study: NCT03385486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TBX-3400
Description: Autologous transfusion
Study: NCT03845868

Intervention type: OTHER
Intervention: Dietary and environmental exposure (Observational study)

Intervention type: OTHER
Intervention: Dietary and environmental exposure (Observational study)
Study: NCT03066557

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE and Apatinib
Description: TACE and Apatinib 250mg po qd

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE
Study: NCT00713180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pterygium excision followed by grafting
Description: Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
Study: NCT03114644

Intervention type: OTHER
Group type: OTHER
Intervention: Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
Description: Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
Study: NCT02642276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
Study: NCT00370604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 19g Tuohy-type epidural needle, 23g catheter
Description: Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
Study: NCT02325856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bioimpedance Spectroscopy
Description: Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Clinical judgement
Study: NCT05530876

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation with virtual game
Description: It will be applied 10 sessions of remote rehabilitation in women with and without breast cancer, in order to promote physical activity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation with virtual game
Description: It will be applied 10 sessions of remote rehabilitation in women with and without breast cancer, in order to promote physical activity.
Study: NCT01604109

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 % w/v CPP-ACP paste
Description: Apply once a day at school by school teacher, following fluoride toothbrushing after lunch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: the paste without CPP-ACP
Description: Apply once a day at school by school teacher, following fluoride toothbrushing after lunch.
Study: NCT03190356

Intervention type: DEVICE
Intervention: Soberlink Cellular Device
Description: Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.

Intervention type: DEVICE
Intervention: Soberlink Cellular Device
Description: Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.
Study: NCT02101112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study: NCT03976401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFX
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFX
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFX
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EFX
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT02795156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
Study: NCT01074047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
Study: NCT02795156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 40 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: 160 mg orally once daily for the first 21 days of each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg orally once daily for each 28-day cycle. Treatment will continue until disease progression or intolerable toxicity or other reason for discontinuation up to 45 months.
Study: NCT01221545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: 3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01788085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bravo pH monitoring procedure
Description: Bravo pH monitoring procedure
Study: NCT04394169

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention program
Description: Medical visits:~There will be three medical visits stipulated as follows:~* Visit 1 Intervention Group, four weeks after hospital discharge.~* Visit 2 Intervention Group, eight weeks after hospital discharge.~* Visit 3 Intervention Group, 18 weeks after hospital discharge.~Components of visits:~* Interview and physical examination.~* Therapeutic education about the intensive care syndrome orally and with a specific document that will be delivered at the end of the visit.~* Therapeutic education around pain. If the patient reports pain, a specific document will be prepared that will be delivered at the end of the visit.~Psychological intervention:~Inclusion criteria for psychological intervention: Patients with a score higher than 8 on the HAD (hospital anxiety and depression) test depression subscale.~Description :~The intervention protocol consists of 7 weekly sessions lasting one hour and a half. The intervention in depression is based on Rehm's model of self-control.
Study: NCT00663858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix 78+78
Description: Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix 78 + Placebo
Description: Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo on Week 0, Week 2, Week 26 and Week 28
Study: NCT01074047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care Regimen
Description: Physician pre-selects prior to randomization from one of the following:~* Intensive chemotherapy (cytarabine 100-200 mg/m\^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles~* Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity~* Best Supportive Care only; until study end
Study: NCT01586273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-HIFU treatment for pain palliation of bone metastases
Description: A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
Study: NCT00700076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine and Org 25935
Description: Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Ketamine
Description: Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
Study: NCT05191264

Intervention type: OTHER
Intervention: EQ5D (EuroQol 5 Dimensions)
Description: The evaluation of the quality of life was conducted with the EQ5D (EuroQol 5 Dimensions) score (min 0: bad health and max:100 good health).

Intervention type: OTHER
Intervention: Numerical Rating Scale (NRS)
Description: the type and intensity of pain will be evaluated by Numerical Rating Scale (NRS) from 0 to 10 in different positions and in different activities (e.g. background pain, general maximum/minimum pain, pain of the site treated by the procedure, pain at rest, in lying position, in sitting position, in standing position, at bearing weight, in walking, description of painful irradiations, nocturnal awakenings).
Study: NCT04379739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: camrelizumab 200mg, q3w, i.v., 2-4 cycles;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: camrelizumab 200mg, q3w, i.v., 2-4 cycles;
Study: NCT00650377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride Tablets 5 mg
Description: 5mg, single dose fed
Study: NCT00370604

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: => 18g Tuohy-type needle
Description: Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
Study: NCT01181765

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg body weight infused over 2 hours
Description: Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
Study: NCT00158431

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopy plus Medical Management
Description: Arthroscopic Surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management
Description: education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
Study: NCT01089543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
Study: NCT03888508

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SIT
Description: sensory integration therapy along with standard therapy.~Primary care giver will be trained to perform sensory integration therapy at home.~. Sensory interventions will include maneuvers for both hypo and hyper-reactive behaviors in five senses as tactile, vestibular, proprioception, vision and auditory using a sensory integration kit and other items available at home~Daily sessions of approx 60 minutes/ day with each sensory stimulus given for 10-30 minutes 6 days in a week will be done.
Study: NCT00650377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proscar® Tablets 5 mg
Description: 5mg, single dose fed
Study: NCT02172781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium - unit dose vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium - unit dose vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ipratropium - unit dose vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium - unit dose vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium - unit dose vial

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium - inhalation capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium - inhalation capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium - inhalation capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium - inhalation capsule
Study: NCT02739243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored group intervention (PREPARE)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual treatment as usual
Study: NCT04381702

Intervention type: PROCEDURE
Intervention: Pancreatoduodenectomy
Description: Open or laparoscopic pancreato-duodenectomy with pancreatojejunal anastomosis

Intervention type: PROCEDURE
Intervention: Pancreatoduodenectomy
Description: Open or laparoscopic pancreato-duodenectomy with pancreatojejunal anastomosis
Study: NCT05191264

Intervention type: OTHER
Intervention: evaluated the consumption of analgesics
Description: the consumption of analgesics by step and by dosage will be evaluated.
Study: NCT03456609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: shenqifuzheng injection
Description: 500ml shenqifuzheng daily（at day 1-14 and day22-36）through intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride Injection 0.9%
Description: 500ml sodium chloride（0.9%）daily（at day 1-14 and day22-36）through intravenous infusion.
Study: NCT02628769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02172781

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching tiotropium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching tiotropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching ipratropium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ipratropium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching ipratropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching ipratropium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching ipratropium
Study: NCT03579303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Homoeopathic Remedies
Description: comparison between homoeopathic treatment and integrated approach of homoeopathy and yoga in menstrual disorders of females with PCOS
Study: NCT01089543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
Study: NCT02030639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rigosertib
Description: A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib (\[14C\]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
Study: NCT03967665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl-L-cysteine
Description: NAC 400 mg three times per day from -14D pre-HSCT to +2 months post-HSCT
Study: NCT02222181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy Management
Description: * assessment of patient characteristics as alcoholic, smoker, food, drugs~* Pharmacotherapy follow-up~* to evaluated medication adherence~* Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention.
Study: NCT02153710

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Semantic Feature Analysis therapy
Description: Control therapy; current standard of care therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phonomotor Therapy
Description: Experimental therapy.
Study: NCT00395538

Intervention type: DRUG
Group type: OTHER
Intervention: PTH 1-34
Description: Given twice daily by subcutaneous